Rituximab, MMF effective alternatives for NMOSD: Study
Rituximab and mycophenolate mofetil may offer the most effective off-label alternatives for NMOSD patients, according to a study.| Neuromyelitis News
No description.| Neuromyelitis News
Rituximab and mycophenolate mofetil may offer the most effective off-label alternatives for NMOSD patients, according to a study.| Neuromyelitis News
Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disease that causes inflammation of the optic nerve and the spinal cord.| Neuromyelitis News
Marisa Wexler is a senior science writer for Neuromyelitis News with an MS in cellular and molecular pathology. She covers the latest news and information on a variety of NMO topics.| Neuromyelitis News
While neuromyelitis optica spectrum disorder's causes are not fully understood, self-reactive antibodies against AQP4 are known major drivers.| Neuromyelitis News
Enspryng (satralizumab-mwge) is an injection therapy approved for adults with neuromyelitis optica spectrum disorder (NMOSD).| Neuromyelitis News
Neuromyelitis optica spectrum disorder affects the optic nerve, spinal cord, and sometimes the brainstem, resulting in a number of symptoms.| Neuromyelitis News
Category archive page for News.| Neuromyelitis News
